Conference Coverage

Bloating. Flatulence. Think SIBO


 

EXPERT ANALYSIS FROM RWCS 2018

Indeed, 40% of patients will experience recurrent SIBO symptoms within 9 months after a round of rifaximin. Recurrences are more common in patients on chronic proton pump–inhibitor therapy, the elderly, and those who have undergone appendectomy. Such patients may need another course of rifaximin once or twice per year.

“If they need rifaximin every 6 months, fine. Patients will be so grateful to you for that course of rifaximin,” Dr. Mahadevan said.

Patients with methane-predominant bacterial overgrowth, as opposed to hydrogen-predominant overgrowth, often benefit from concomitant neomycin at 500 mg twice per day along with their 10-14 days of rifaximin.

“A lot of our cirrhotic patients are on both,” she noted.

Pages

Recommended Reading

Perioperative infliximab does not increase serious infection risk
MDedge Dermatology
Humira Pen topped per-person drug spending in 2016
MDedge Dermatology
DTC genetic health risk tests: Beware
MDedge Dermatology
Infliximab biosimilar noninferior to originator in IBD – NOR-SWITCH
MDedge Dermatology
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Dermatology
Launch of adalimumab biosimilar Amjevita postponed
MDedge Dermatology
Biosimilars poised to save $54 billion over the next decade
MDedge Dermatology
Neoantigen profiling predicts response to immunotherapy
MDedge Dermatology
Breakthrough cancer gene assay approved, CMS proposes coverage
MDedge Dermatology
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
MDedge Dermatology